Patisiran: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Patisiran. Educational only — not medical advice.
Labeled uses
ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Source: FDA labeling via NIH DailyMed (set e87ec36f…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.